The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]-pyrimidine-2-(1H) -one (YM-64227), a phosphodiesterase type 4 inhibitor

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 800-806

  Tenmizu, Daisuke ^a   Noguchi, Kiyoshi ^a   Kamimura, Hidetaka ^a   Ohtani, Hisakazu ^b   Sawada, Yasufumi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYCLOHEXYL 1 ETHYL 7 METHYLPYRIDO[2,3 D]PYRIMIDINE 2 (1H)ONE; CYTOCHROME P450 1A2; DRUG METABOLITE; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; YM 64227;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOCHROME P450 1A2 DEFICIENCY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME DEFICIENCY; GENOTYPE; LIVER MICROSOME; MALE; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; BIOTRANSFORMATION; CYCLOHEXANES; CYTOCHROME P-450 CYP1A2; DOGS; GENOTYPE; INJECTIONS, INTRAVENOUS; MALE; MICROSOMES, LIVER; PHOSPHODIESTERASE INHIBITORS; POLYMORPHISM, GENETIC; PROTEIN BINDING; PYRIMIDINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 33645836150     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008722     Document Type: Article

References (31)

1. Akaike H (1969) Fitting autoregressive models for prediction. Ann Inst Stat Math 21:243-247.
2. Azuma R, Komuro M, Kawaguchi Y, Okudaira K, Hayashi M, and Kiwada H (2002) Comparative analysis of in vitro and in vivo pharmacokinetics parameters related to individual variability of GTS-21 in canine. Drug Metab Pharmacokinet 17:75-82.
3. Bischoff KB, Dedrick RL, Zaharko DS, and Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133.
4. Blaisdell J, Goldstein JA, and Bai SA (1998) Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26:278-283.
5. Ciaccio PJ, Graves PE, Bourque DP, Glinsmann-Gibson B, and Halpert JR (1991) cDNA and deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. Biochim Biophys Acta 1088:319-322.
6. Dedrick RL, Forrester DD, Cannon JN, El Dareer SM, and Mellett LB (1973) Pharmacokinetics of 1-[beta]-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem Pharmacol 22:2405-2417.
7. Fraser DJ, Feyereisen R, Harlow GR, and Halpert JR (1997) Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283:1425-1432.
8. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, and Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561.
9. Graves PE, Elhag GA, Ciaccio PJ, Bourque DP, and Halpert JR (1990) cDNA and deduced amino acid sequences of a dog hepatic cytochrome P450IIB responsible for the metabolism of 2,2′,4,4′,5,5′-hexachlorobiphenyl. Arch Biochem Biophys 281:106-115.
10. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
11. Iwatsubo T, Hirota N, Ooie T, Suzuki H, and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
12. Kagimoto M, Heim M, Kagimoto K, Zeugin T, and Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214.
13. Knaak JB, al-Bayati MA, Raabe OG, and Blancato JN (1993) Development of in vitro Vmax and Km values for the metabolism of isofenphos by P-450 liver enzymes in animals and human. Toxicol Appl Pharmacol 120:106-113.
14. Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD, and Josephs H (1982) The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 32:261-269.
15. Lankford SM, Bai SA, and Goldstein JA (2000) Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos 28:981-986.
16. Lin JH, Sugiyama Y, Awazu S, and Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 10:649-661.
17. Mise M, Yadera S, Matsuda M, Hashizume T, Matsumoto S, Terauchi Y, and Fujii T (2004) Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos 32:240-245.
18. Montandon B, Roberts RJ, and Fischer LJ (1975) Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J Pharmacokinet Biopharm 3:277-290.
19. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
20. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
21. Pantuck EJ, Kuntzman R, and Conney AH (1972) Decreased concentration of phenacetin in plasma of cigarette smokers. Science (Wash DC) 175:1248-1250.
22. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, and Schoenhard GL (1999) Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27:1133-1142.
23. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, and Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
24. Roberts MS and Rowland M (1986a) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm 14:227-260.
25. Roberts MS and Rowland M (1986b) Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38:177-181.
26. Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R, Takanaka A, and Matsubara T (1995) A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 319:372-382.
27. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, and Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
28. Tantcheva-Poor I, Zaigler M, Rietbrock S, and Fuhr U (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9:131-144.
29. Tenmizu D, Endo Y, Noguchi K, and Kamimura H (2004a) Identification of the novel canine CYP1A2 1117 C>T SNP causing protein deletion. Xenobiotica 34:835-846.
30. Tenmizu D, Fukunaga Y, Noguchi K, and Kamimura H (2004b) Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection. Biomed Chromatogr 18:667-672.
31. Uchida T, Komori M, Kitada M, and Kamataki T (1990) Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol Pharmacol 38: 644-651.